Recruiting
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
NCT03801434
- Conditions
- BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, +17 more
- Locations
-
- Stanford Cancer Institute Palo Alto Palo Alto, California, United States
- OHSU Knight Cancer Institute Portland, Oregon, United States
- University of Utah Salt Lake City, Utah, United States
- Fred Hutchinson cancer research center Seattle, Washington, United States